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Abstract: Antibiotics, along with oral corticosteroids, are standard treatments for acute 
  exacerbations of chronic obstructive pulmonary disease (AECOPD). The ultimate aims of treatment 
are to minimize the impact of the current exacerbation, and by ensuring complete resolution, reduce 
the risk of relapse. In the absence of superiority studies of antibiotics in AECOPD, evidence of the 
relative efficacy of different drugs is lacking, and so it is difficult for physicians to select the most 
effective antibiotic. This paper describes the protocol and rationale for MAESTRAL (moxifloxacin 
in AECBs [acute exacerbation of chronic bronchitis] trial; www.clinicaltrials.gov: NCT00656747), 
one of the first antibiotic comparator trials designed to show superiority of one antibiotic over another 
in AECOPD. It is a prospective, multinational, multicenter, randomized, double-blind controlled 
study of moxifloxacin (400 mg PO [ per os] once daily for 5 days) vs amoxicillin/clavulanic acid 
(875/125 mg PO twice daily for 7 days) in outpatients with COPD and chronic bronchitis suffer-
ing from an exacerbation. MAESTRAL uses an innovative primary endpoint of clinical failure: 
the requirement for additional or alternate treatment for the exacerbation at 8 weeks after the end 
of antibiotic therapy, powered for superiority. Patients enrolled are those at high-risk of treatment 
failure, and all are experiencing an Anthonisen type I exacerbation. Patients are stratified accord-
ing to oral corticosteroid use to control their effect across antibiotic treatment arms. Secondary 
endpoints include quality of life, symptom assessments and health care resource use.
Keywords: AECOPD, moxifloxacin, amoxicillin/clavulanic acid, clinical trial design, exacer-
bation, antibiotic
Introduction
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD), which is 
usually associated with chronic bronchitis, drive progressive lung function decline in 
patients,1–3 are major contributors to mortality, morbidity and reductions in quality of life,4–9 
and the resulting hospitalizations markedly increase health care costs.7,10 The mainstays 
of AECOPD treatment are intensification or addition of short-acting bronchodilators, 
and in selected patients, antibiotics with or without systemic corticosteroids.5,11 However, 
treatment failure rates in many recent antibiotic studies are high, which could be related 
to inadequate antibiotic efficacy.12,13 Incomplete resolution of the initial exacerbation may 
also influence the risk of relapse: many patients experience a further exacerbation within a 
few weeks,13,14 with relapse rates varying between antibiotics.14 Therefore, it is likely that 
improving clinical outcomes requires the use of the most effective antibiotic available.
Proof of superiority of one antibiotic over another in AECOPD is lacking,5,11 as 
are high-quality clinical data to inform clinical guidelines.15,16 Although there are 
many comparative studies of different antibiotics in AECOPD, no single drug has yet 
shown superiority for the primary endpoint in a clinical trial. This lack of evidence of International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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superiority is in part because many studies were powered 
only for noninferiority, but may also be due to issues of 
patient selection (patient characteristics predating the cur-
rent exacerbation can negatively affect outcomes) and end-
point selection in clinical trials.11,15,17,18
There is a clear unmet need for superiority trials in 
AECOPD,19 in particular between antibiotics commonly 
used in AECOPD and in patients at high risk of poor 
clinical outcomes who are most likely to benefit from the 
most effective therapies.11,18,19 While trials of antibiotics 
in AECOPD have yet to show superiority for the primary 
endpoint, some have demonstrated superiority for second-
ary endpoints, the most recent of which was the MOSAIC 
study.20 This compared moxifloxacin and a basket of com-
parators (amoxicillin/clarithromycin/cefuroxime axetil) 
in patients with Anthonisen type I exacerbations21 and 
mild-to-moderate COPD. In MOSAIC, moxifloxacin was 
superior to comparator antibiotics for clinical cure (defined 
as a return to baseline health status) and bacterial eradica-
tion. Longer-term outcomes from MOSAIC showed that 
moxifloxacin was also superior to comparators in terms of 
lower relapse rates.20
This paper describes the MAESTRAL (moxifloxacin 
in AECBs [acute exacerbation of chronic bronchitis] trial; 
  clinical trial.gov number: NCT00656747) study design and 
the rationale for its novel features. These include powering the 
study for superiority testing, selection of chronic bronchitis 
patients with moderate-to-severe COPD and assessment of 
the utility of an 8-week clinical endpoint.
MAESTRAL methodology
Study design
MAESTRAL is a prospective, multinational, multicenter, 
randomized, double-blind, double-dummy controlled study. 
The primary objective of MAESTRAL is to compare the 
efficacy of a 5-day course of moxifloxacin to that of a 7-day 
course of amoxicillin/clavulanic acid in the treatment of 
outpatients experiencing AECOPD who are at high risk 
of treatment failure. The study is powered to show clinical 
superiority between antibiotic treatments. It uses an innova-
tive clinical endpoint of clinical failure rates over an 8-week 
period after treatment with an antibiotic. The study design 
is shown in Figure 1.
Study population
Inclusion and exclusion criteria
Outpatients with COPD and chronic bronchitis suffering 
from an exacerbation are enrolled in the MAESTRAL study. 
Patients must be $60 years old, have a documented history 
of $2 exacerbations within the previous year requiring a 
course of systemic antibiotics and/or systemic corticos-
teroids, postbronchodilator forced expiratory volume in 
1 second (FEV1) #60% predicted, FEV1/forced vital capac-
ity (FVC) ,70%, and be current or past cigarette smokers 
with a $20 pack-year smoking history. They must also be 
experiencing an Anthonisen type I exacerbation (the presence 
of all three of purulent sputum, increased sputum volume, 
and increased dyspnea21 as confirmed by the investigator) 
and be suitable for treatment with oral antibiotics. Patients 
must also be exacerbation-free for at least 30 days prior to 
enrollment.
The main exclusion criteria are contraindications to study 
drugs, immunosuppression, structural lung diseases (for 
example, known diffuse bronchiectasis), and systemic anti-
biotics or corticosteroids within 30 days prior to enrollment. 
The full list of exclusion criteria is given in Supplementary 
Section 1.
Stratification by steroid use
To ensure an even distribution between treatment arms of 
patients receiving corticosteroids, patients are stratified 
according to the coadministration of a short course (5 days) 
of systemic corticosteroid therapy (30–40 mg/day of predni-
solone or equivalent) for the current exacerbation, where the 
first dose is administered on the same or next day as the study 
drug (Figure 1 and Supplementary Section 2).   Following the 
end of this 5-day course of steroid treatment, down-titration 
for up to 5 days is allowed. Agents used to manage the ongo-
ing COPD (long-acting bronchodilators and inhaled corti-
costeroids) will be maintained on a stable dose and regimen 
during treatment and for the 8 weeks of follow-up. The choice 
Multinational, multicenter, randomized double-blind controlled trial in 
COPD patients with acute exacerbation
Patients enrolled at exacerbation 
Oral corticosteroid use No oral corticosteroid use
Moxifloxacin 400 mg PO once daily for 5 days or
Amoxicillin/clavulanic acid 875/125 mg PO twice daily for 7 days
Randomization 1:1
Stratification by steroid use
Follow up
Primary endpoint :
Clinical failure rates at 8 weeks post-therapy
Any failures/relapses occurring before 8 weeks post-therapy
are carried forward to the primary endpoint
Figure 1 MAeSTRAL study design.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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of steroids is at the treating physician’s discretion within 
guidelines set out in the study protocol. All comedications 
will be recorded for the duration of the study.
ethical approval
All patients must provide written informed consent, accord-
ing to the International Conference on Harmonisation Good 
Clinical Practice Guidelines and local legal requirements. 
The study is being carried out according to Good Clinical 
Practice Guidelines and according to the principles of the 
Declaration of Helsinki. Documented approval has been 
obtained from the appropriate ethical committees and Insti-
tutional Review Boards.
Microbiology
Spontaneous sputum samples are to be obtained from all 
patients, assessed in a local laboratory, and examined for the 
presence of polymorphonuclear cells, squamous epithelial 
cells, and bacteria. All potentially pathogenic bacteria (PPB) 
are to be identified (Streptococcus pneumoniae, Moraxella 
catarrhalis, Pseudomonas aeruginosa, Haemophilus spp., 
Enterobacteriaceae spp., and Staphylococcus aureus) and 
pure subcultures frozen and subsequently forwarded to a cen-
tral microbiology laboratory. There, they will be re-identified 
and minimum inhibitory concentrations (MICs) determined 
for moxifloxacin and amoxicillin/clavulanic acid and a range 
of other antibiotics by the reference Clinical Laboratory 
Standards Institute broth microdilution method.22 MICs for 
penicillin are determined for S. pneumoniae, and meticillin 
resistance is determined in S. aureus.
Antibiotic treatments
Patients receive either moxifloxacin (Bayer Schering Pharma, 
Wuppertal, Leverkusen or Berlin, Germany) 400 mg PO once 
daily for 5 days or amoxicillin/clavulanic acid (STADAp-
harm GmbH, Bad Vilbel, Germany) 875/125 mg PO twice 
daily for 7 days. Moxifloxacin and amoxicillin/clavulanic 
acid are well established as effective therapies for exacerba-
tions of COPD and chronic bronchitis with good clinical 
and bacteriological efficacy in AECOPD.23–25 They are also 
both included within guidelines as recommended therapies 
for patients with moderate-to-severe exacerbations.15,16 The 
dose chosen for both drugs is that recommended in Euro-
pean guidelines15 and is in common use in the regions where 
MAESTRAL is being carried out. The pharmacokinetic/
pharmacodynamic (PK/PD) properties of both drugs sug-
gest that they are an adequate treatment for S. pneumoniae 
isolates with an MIC #2 mg/L.26 Importantly, the dose of 
  amoxicillin/clavulanic acid chosen (875/125 mg PO twice 
daily for 7 days) has a comparable clinical efficacy and 
safety profile to a higher dose, shorter course of long-acting 
amoxicillin/clavulanic acid (2000/125 mg PO twice daily 
for 5 days).24
Clinical and bacteriological 
endpoints
The primary efficacy endpoint of MAESTRAL is clinical 
failure at the 8-weeks post-therapy visit. Clinical failure is 
defined as the requirement for additional or alternate treat-
ment with systemic antibiotics and/or systemic corticoster-
oids (including increased dose or duration of treatment), 
and/or hospitalization within 8 weeks post-therapy for an 
exacerbation of respiratory symptoms. Clinical failures 
occurring during therapy or follow-up are carried forward 
until 8 weeks post-therapy. Clinical failures occurring dur-
ing therapy or follow-up are carried forward until 8 weeks 
post-therapy.
A range of secondary endpoints is also defined; the full 
list is given in Table 1. These include clinical response rates 
at interim time points and bacteriological outcome at all 
time points, lung function tests, medication use, and quality 
of life (St George’s Respiratory Questionnaire [SGRQ])27 
and symptom assessments (Acute Exacerbation of Chronic 
Bronchitis Symptom Scale [AECB-SS]).28,29
Clinical and bacteriological efficacy 
assessments
The study consists of the following visits: enrollment/
randomization (day 1 is the first day of study drug treat-
ment), during therapy (treatment day 4 ± 1), end of therapy 
(day 13 ± 1 after start of study drug treatment), 4 weeks 
post-therapy (day 35 ± 3 after start of study drug treatment), 
and 8 weeks post-therapy (day 63 ± 3 after start of study 
drug treatment). Data collected at each visit are shown in 
Table 2.
Assessment of clinical response to therapy is based on 
determination of the effect of therapy on auscultatory find-
ings, chest pain/discomfort, cough frequency, dyspnea, 
sputum purulence, sputum consistency, and sputum volume. 
Clinical response is assessed as: clinical improvement (during 
therapy only), clinical failure, indeterminate, clinical cure, 
continued clinical cure, and clinical relapse (definitions are 
given in Supplementary Section 3). Clinical failure rates 
can be assessed during nonprotocol-defined visits as well as 
during therapy, at end of therapy, and at the 4 and 8-week 
post-therapy visits. Premature discontinuations due to study International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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drug failure will also be treated as failures. For patients who 
discontinue study drug for reasons other than efficacy, the 
assessment at 8-week post-therapy visit will be used where 
completed. For those patients who do not return for the 
8-week post-therapy visit, the response will be considered 
missing. These patients will be excluded from the per protocol 
population as will those with an indeterminate clinical out-
come at the last available assessment.
The categories of bacteriological response to therapy are: 
eradication without superinfection or reinfection, presumed 
eradication, persistence, presumed persistence, eradication 
with superinfection, eradication with reinfection, eradication 
with recurrence, continued eradication, continued presumed 
eradication, and indeterminate (see Supplementary Section 3). 
Bacteriological response rates are assessed during therapy, 
at end of therapy and at 4 and 8 weeks post-therapy.
Data Review Committee
There has been some concern in previous antibiotic studies 
regarding inconsistent assessment of clinical outcomes by 
treating physicians. To validate the physician’s assessment 
of clinical outcomes an independent Data Review Commit-
tee (DRC) will assess the data for all clinical failures and 
indeterminate assessments prior to the unblinding of the treat-
ment assignment of datasets. Their objective is to confirm 
the primary clinical outcome and to validate the inclusion of 
the patient’s data in the primary analysis.
Safety assessments
The safety of treatment is monitored by clinical observations 
at each visit following enrollment. All adverse events (AEs) 
are recorded up to 8 weeks post-therapy. All AEs are assessed 
in terms of their severity, intensity (mild, moderate or severe), 
and relationship to the study drug. Investigators are asked 
to monitor any patients with diarrhea, and if Clostridium 
difficile-related diarrhea is suspected, investigators are asked 
to take appropriate clinical measures, including C. difficile 
toxin detection and remedial therapy where warranted.
Analyses
Efficacy populations
The primary population for assessment of clinical outcomes is 
the per protocol (PP) population. These patients have all had an 
acute exacerbation at enrollment and have received the study 
drug for a minimum of 48 hours (cases of clinical failure) or 
received $80% of study medication (cases of clinical cure). All 
have data for clinical evaluation at 8 weeks post-therapy (except 
for clinical failures prior to the 8 weeks post-therapy visit) and 
have no protocol violations. The intent-to-treat (ITT)/safety 
population includes all patients randomized who received at least 
one dose of study drug and with one observation after initiation 
of study treatment. The microbiologically valid population is 
drawn from the PP population and comprises all patients with 
at least one PPB cultured from sputum provided prior to start of 
therapy and where a bacteriological evaluation is available during 
Table 1 Secondary endpoints
Category Endpoint
Clinical failure measures • Clinical failure rates during therapy, at end of therapy and at 4 weeks post-therapy
•   Clinical failure rates (for patients with positive sputum culture at enrollment) during therapy, at end 
of therapy, and at 4 and 8 weeks post-therapy
• Clinical failure rates for patients with coadministration of systemic corticosteroids
• Clinical failure rates for patients without coadministration of systemic corticosteroids
Bacteriological outcomes •   Bacteriological eradication rates during therapy, at end of therapy, and at 4 and 8 weeks post-therapy
Symptom burden and quality of life • Weekly mean symptom scores measured by the AeCB-SS
• Rates and speed of symptom relief measured by the AeCB-SS
• Changes in symptom burden measured by the AeCB-SS
• Changes in health-related quality of life measured by the SgRQ
• Lung function (spirometry): between-group comparisons at each assessment visit
Comedications and health care  
resource use
•   Need for any change in dosage or additional respiratory medication such as bronchodilators and 
inhaled corticosteroids, but excluding short-acting bronchodilators
•   health care resource use/consumption related to COPD/chronic bronchitis management including 
rescue medications, concomitant medications, therapeutic adjuncts, diagnostic procedures, other 
medical care/medical staff requirements, hospitalizations, and work productivity and activity 
impairment
Safety •   Safety and tolerability of moxifloxacin versus amoxicillin/clavulanic acid, with particular attention to 
rates of diarrhea
Abbreviations: AeCB-SS, Acute exacerbation of Chronic Bronchitis Symptom Scale; COPD, chronic obstructive pulmonary disease; SgRQ, St george’s Respiratory 
Questionnaire.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Data collected at each study visit
Assessment Visit
Enrollment/ 
randomization  
(day 1 is the first day  
of treatment)
During therapy  
(treatment day  
4 ± 1 day)
End of therapy  
(day 13 ± 1 day  
after start of  
treatment)
Four weeks  
post-therapy  
(day 35 ± 3 days after  
start of treatment)
Eight weeks  
post-therapy  
(day 63 ± 3 days after   
start of treatment)
Sputum specimens  
for bacteriological  
examination (macroscopic  
assessment of purulence,  
microscopic evaluations,  
and culture)
    
Clinical responsea –    
Spirometry     
AeCB-SS questionnaire  
(daily from start of  
treatment to end  
of therapy visit and 
at post-therapy visits)
   – –
SgRQ (self-administered  
at each visit)
 –   
health care resource  
consumption related to  
AeCOPD/COPD (all  
resource use recorded)
    
Adverse events,  
concomitant medications 
(recorded at each visit)
    
Changes in respiratory  
symptoms
–    
Notes: aIf the subject did not improve during therapy, or experienced a relapse, an unscheduled clinic visit (premature discontinuation) was booked and the subject 
underwent all 8 weeks post-therapy visit evaluations prior to initiation of an additional or alternative treatment; if the investigator assessment was clinical failure, the subject 
was prematurely terminated from the study and was not followed further.
Abbreviations: AeCB-SS, Acute exacerbation of Chronic Bronchitis Symptom Scale; SgRQ, St george’s Respiratory Questionnaire.
the study. The ITT with causative organisms population includes 
patients valid for ITT with at least one pretherapy PPB.
Statistics
Sample size calculation
To power MAESTRAL for superiority, the objective is to 
ensure that 540 valid PP patients are enrolled in each treat-
ment arm; therefore, at least 1350 COPD patients with an 
Anthonisen type I exacerbation21 are required to be random-
ized. Patients will be drawn from across 30 countries. This 
high number of patients is driven by a 6% margin – a more 
rigorous definition of failure rates than the standard 10% 
normally used in noninferiority trials.30
Primary analysis
The primary aim of the study is to show noninferiority (defined 
as a difference in failure rates of #6% using a   one-sided test 
at a level of 2.5%) of moxifloxacin vs   amoxicillin/clavulanic 
acid in the PP population. If   noninferiority is statistically 
proven, the possibility that moxifloxacin is superior to 
amoxicillin/clavulanic acid will be tested in the ITT popula-
tion, using a one-sided test at the 2.5% level. The primary 
ITT analysis will be clinical failure vs all other evaluations 
(clinical cure, indeterminate, and missing). Two sensitivity 
analyses are planned: (1) missing responses will be combined 
with indeterminates and clinical failures in an overall nonsuc-
cess category, and (2) missing and indeterminate responses 
will be excluded and only cures or failures will be considered. 
The 95% two-sided confidence interval (CI) of the difference 
of two clinical failure rates (treatment group ‘moxifloxacin’ 
minus treatment group ‘amoxicillin/clavulanic acid’) will 
be calculated using Mantel–Haenszel weights for the strata 
(geographic region and stratification by corticosteroid use, 
as outlined in Supplementary Section 2). If the upper limit of 
the CI is ,6%, it will prove that treatment with moxifloxacin 
is clinically no less effective than treatment with amoxicillin/International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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clavulanic acid. If the upper limit of this CI is ,0, superiority 
of treatment with moxifloxacin will be proven. To check the 
appropriateness of the calculation of the Mantel–Haenszel 
weighted CIs, the Breslow–Day test, or Zelen’s test, will 
be performed to test for homogeneity of odds ratios across 
strata. If the test indicates a treatment-by-stratum interaction, 
exploratory analyses will be performed to find the source 
of this interaction. If such a source is found, the Mantel–
Haenszel weighted CI will be calculated using weighting 
based on variables explaining the interaction.
Demographic and baseline characteristics will be sum-
marized by treatment group for the PP and ITT populations 
and compared using the Cochran–Mantel–Haenszel test 
adjusted for strata and region.
Secondary clinical and bacteriological endpoints will be 
analyzed as for the primary analysis, but using appropriate 
patient populations and time points. Clinical and bacteriologi-
cal outcomes at a variety of time points (during therapy, end 
of therapy, 4 weeks post-therapy, and 8 weeks post-therapy) 
will be investigated in subpopulations of special interest, 
such as those with and without coadministration of systemic 
corticosteroids. The full list of subpopulations of interest is 
given in Supplementary Section 4.
AECB-SS and SGRQ scores will be determined and 
analyzed separately. The main analysis for the SGRQ data 
will compare the mean change from baseline in the total 
SGRQ score between treatment groups 8 weeks after the end 
of therapy. For AECB-SS, the means, standard deviations, 
medians, minimums, and maximums will be provided for the 
total score and change from baseline in total score at each 
visit, by treatment group. For health care resource use, if the 
homogeneity of between-country resource consumption is 
satisfactory, the data will be pooled, summarized, and 95% 
CIs estimated.
For the safety analysis, a Cochran–Mantel–Haenszel test 
will assess the difference in incidence rates between treat-
ment groups for the overall rate of premature discontinua-
tions, discontinuations due to AEs, and discontinuations due 
to insufficient therapeutic effect. Other safety data will be 
tabulated; vital signs will be analyzed descriptively.
Discussion
Clinical trials of antibiotics in AECOPD have tradition-
ally been short-term, included relatively small numbers 
of patients, and focused largely on the cure of an existing 
exacerbation. Most of these trials have been powered to show 
noninferiority, making it difficult for physicians to select the 
‘best’ antibiotic for a particular patient.11,31,32 MAESTRAL 
aims to address all these issues by recruiting sufficient 
patients (n $1350) to allow the study to be powered for 
superiority and by setting an innovative long-term primary 
endpoint of clinical failure at 8 weeks post-therapy.
Traditional clinical trial endpoints occur soon after the 
end of treatment and cannot provide data on clinical failures 
or relapse rates occurring more than 2 or 3 weeks post-
treatment.11,31 Consequently, they may not be long enough to 
reveal any clinically relevant differences in treatment regimens 
that emerge in the weeks following the completion of thera-
py.33 Indeed, it has been suggested that future clinical trials 
should be designed to assess longer-term endpoints.34,35 The 
suitability of an endpoint measured 8 weeks from the end of 
antibiotic treatment is supported by the fact that patients tend 
to relapse and exacerbations cluster such that there is a high 
risk of recurrent exacerbation in the 8 weeks after an initial 
exacerbation.33 In addition, in the MOSAIC study, the most 
significant differences between treatments in terms of time-to-
treatment failure, relapse, or requirement for further antibiot-
ics occurred during the first 8 weeks after treatment.36
Patient selection is a recurring problem in published 
trials. It is now well established that underlying patient 
characteristics such as older age, higher exacerbation fre-
quency, presence of concomitant cardiopulmonary disease, 
and a higher severity of underlying airway obstruction 
are key determinants of poor outcome in AECOPD.23,36,37 
  Exacerbations become more frequent and more severe as the 
underlying COPD progresses, but some patients have more 
exacerbations than others, which appears to be an indepen-
dent susceptibility phenotype.38 Those who are particularly 
susceptible to exacerbations have worse health status and 
faster disease progression than infrequent exacerbators.38,39 
One explanation might be that some patients remain at 
high risk for recurrent exacerbation in the 8-week period 
after initial exacerbation,33 possibly due to differing levels 
of ongoing lung and systemic inflammation in frequent and 
infrequent exacerbators.40 In most published antibiotic trials 
to date, patient populations are highly heterogeneous and may 
include relatively young and fit patients as well as those who 
are elderly and/or more severely ill. Indeed, there is even a 
lack of consensus on how to define patients’ illnesses. While 
distinctions are made between acute exacerbation of chronic 
bronchitis (AECB) and AECOPD, COPD, and chronic 
bronchitis often coexist, are treated in parallel in the clini-
cal setting, and most antibiotic intervention studies include 
patients with and without documented airflow obstruction. 
Enrollment of patients with AECB, mild COPD, or normal 
lung function will dilute the actual effect and increase the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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perceived efficacy of antibiotics due to high spontaneous 
rates of recovery. This makes it harder to show superiority 
of one antibiotic over another,11,31 as most of these patients 
would recover even without an antibiotic. As individuals 
at high risk of poor outcomes have high rates of failure 
and relapse,23,41 MAESTRAL is enriched with patients at 
risk of poor outcomes (ie, those $60-years-old who have 
experienced $2 exacerbations in the previous year, have 
moderate-to-severe COPD according to the GOLD spiro-
metric criteria,16 and who are experiencing an Anthonisen 
type I exacerbation).
Patients with COPD are likely to be taking a range of 
medications to treat the exacerbation, the underlying COPD, 
and any concomitant illness. However, in many trials there is 
only limited evaluation of concurrent medication, the use of 
which could affect clinical outcome and create bias between 
antibiotic treatment groups.31 MAESTRAL tackles this issue 
by recording all concomitant medications for the full duration 
of the study. Physicians are instructed not to change patients’ 
regular maintenance inhaled and oral COPD therapy during 
the study, but the need for any change in dosage or additional 
respiratory medication, such as bronchodilators and inhaled 
steroids, will be assessed.
Treatment of the current exacerbation often requires an 
antibiotic plus one or more other treatments, such as oral corti-
costeroids or an increased dose of a long-acting beta-agonist.9,11 
To date, whether antibiotics are of benefit in moderate-to-severe 
exacerbations when a short course of corticosteroids is coad-
ministered has been studied in very few large, well-designed 
trials.9,11,12 Because steroids can assist in the clinical resolution 
of an exacerbation, inconstant steroid treatment in the arms of 
an antibiotic trial can confound interpretation of the results. 
Mandating oral corticosteroids in all patients or making their 
use an exclusion criteria in this study are both inconsistent 
with current guidelines and make recruitment in a large study 
difficult. In MAESTRAL, the unique approach of stratifying 
patients for the concomitant use of oral corticosteroids to treat 
the current exacerbation is used to control for the use of con-
comitant corticosteroids. However, no inference on the clinical 
efficacy of steroid treatments can be drawn from this study 
because the allocation of steroids was not randomized.
Ensuring that patients most likely to be experiencing a 
bacterial (as opposed to, for instance, viral) exacerbation 
are enrolled in the trial is an important aspect of the MAES-
TRAL study design. Therefore, an Anthonisen type I exac-
erbation must be confirmed by the investigators. Where an 
AECOPD has a bacterial etiology, symptom resolution of that 
exacerbation will likely be influenced by bacterial eradication; 
the underlying mechanism is thought to be due to resolution 
of the inflammatory response to bacteria.42 By choosing 
patients with Anthonisen type 1 exacerbations, the study 
population is enriched with patients in whom bacteria play a 
significant role and who should benefit most from antibiotic 
therapy. Anthonisen type I exacerbations have been shown to 
have a high frequency of bacterial pathogen isolation.4
The MAESTRAL study uses recommended antibiotics, 
moxifloxacin and amoxicillin/clavulanic acid. Both drugs are 
commonly used for therapy of more severely ill patients with 
an AECOPD in most countries where the MAESTRAL trial 
is conducted, are recommended in a number of guidelines 
for this patient group,16,43 and have shown good efficacy in 
AECOPD.23,24 Furthermore there is evidence that fluoro-
quinolones, such as moxifloxacin, have resulted in better 
bacteriological eradication than some other drug classes.23 
This was seen in the MOSAIC study,20 in which moxifloxacin 
was equivalent to standard comparators for short-term clinical 
outcomes, but was superior with respect to bacteriological 
eradication and resulted in fewer exacerbations in the 8 weeks 
following treatment than comparators.20 MAESTRAL has 
built upon the design and outcomes of MOSAIC in a number 
of ways. As well as using the 8-week endpoint, MAESTRAL 
enrolls patients identified in a post hoc analysis of MOSAIC 
data as having a high risk of relapse.
In the majority of noninferiority trials, sample size is 
calculated in order to detect a difference between treatment 
groups in failure rates of ,10%. Conversely, in   MAESTRAL, 
the high number of patients recruited was driven by a 6% 
margin for noninferiority, which is a much more rigorous 
definition. The use of a superiority protocol follows Food and 
Drug Administration guidance on trial design, which cautions 
that noninferiority trials have previously failed to show a ben-
efit of one antibiotic over another.44 A further novel element 
in the design of MAESTRAL is the inclusion of AECB-SS 
and SGRQ questionnaires. Such patient-reported outcomes 
can provide important insights into clinical outcomes like 
symptom improvement and quality of life, as well as provid-
ing information that will enable the DRC to make informed 
decisions about the true clinical outcomes. Use of repeated 
spirometry measurements in MAESTRAL is also an innova-
tive feature for an antibiotic trial, ensuring that only patients 
with moderate or severe COPD are enrolled and providing 
another means of monitoring response to treatment.
DRC members receive patient information in a blinded fash-
ion for those who were clinical failures or had an indeterminate 
response. Through assessment of all documented clinical 
information and investigator decisions (although the DRC are International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
380
Wilson et al
blinded to clinical outcome assessments by investigators), the 
DRC is able to assess whether the patient is a true failure or 
relapse. This includes going back to investigators via the study 
managers (ie, in a blinded fashion) to challenge a decision. 
For example, when the clinical information suggests a clini-
cal relapse, but antibiotic or oral steroid are not prescribed, it 
may be because the patient attended another clinic; whereas 
when clinical information suggests stability, but an antibiotic 
or steroid are prescribed, further questioning of the investigator 
could reveal that it was not prescribed for a relapse. The DRC 
also decides, based on prescribing habits, on steroid use that is 
a violation of protocol vs steroid use that is continued because 
of persistent symptoms, ie, clinical failure.
There are potential limitations to the design of 
  MAESTRAL. The choice of clinical failure at 8 weeks post-
therapy as the primary endpoint is based on the best evidence 
available, but may not prove to be the optimum duration – 
potentially an even longer timescale might be desirable. How-
ever, it should also be noted that long-term follow-up can be 
subject to multiple confounders. Additionally, while steps 
have been taken to control for concomitant medications and 
oral corticosteroid use, stratification was limited to corti-
costeroid use and not undertaken for the use of long-acting 
bronchodilator and/or inhaled corticosteroids (though the 
inhaled medications were used at a stabilized dose).
Despite these limitations, it is anticipated that   MAESTRAL 
will provide further evidence as to the most appropriate study 
design for trials of antibiotics in AECOPD, and it should also 
provide some information about the extent of the relative roles 
of antibiotics and systemic corticosteroids in the treatment of 
AECOPD. Irrespective of whether noninferiority or superiority is 
achieved, the results should add further to the debate on optimal 
trial design in this condition. It is hoped that MAESTRAL may 
also help to inform guidelines and allow physicians to optimize 
clinical outcomes and reduce AECOPD-related health care costs 
through appropriate patient profiling and antibiotic choice.
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Supplementary material
Supplementary section 1: Full list of exclusion criteria
  1. Known hypersensitivity to quinolones, beta-lactams, or to any of the excipients of the study drugs.
  2. Pregnant or breastfeeding women (women of childbearing potential, based on investigator assessment, must have negative urinary pregnancy test).
  3. Congenital or acquired QT prolongation.
  4. Clinically relevant bradycardia.
  5. Clinically relevant heart failure with reduced left-ventricular ejection fraction.
  6. Previous history of symptomatic arrhythmias.
  7.   Taking QT prolonging drugs, for example Class Ia or III anti-arrhythmic agents (eg, quinidine, procainamide, amiodarone, sotalol), neuroleptics 
(eg, phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressants, certain antihistaminics (eg, terfenadine, astemizole, 
mizolastine), certain antimicrobials (sparfloxacin; erythromycin IV; pentamidine; antimalarials, particularly halofantrine), or other QT prolonging 
drugs (eg, cisapride, intravenous vincamine, bepridil, and diphemanil).
  8. Uncontrolled electrolyte disturbances, particularly uncorrected hypokalaemia.
  9. History of hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.
10. history of a tendon disease/disorder.
11.   history of liver dysfunction (Child-Pugh C), including elevated transaminase levels (alanine aminotransferase and/or aspartate aminotransferase .5 
times the upper limit of normal).
12. Severe renal impairment with glomerular filtration rate of ,30 mL/min.
13. Neutropenia (neutrophil count , 1000/mm3) caused by immunosuppressive therapy or malignancy.
14. AIDS (CD4 count of , 200/mm3), or hIV positive and receiving highly active anti-retroviral therapy (testing for hIV is not mandatory).
15.   Chronic asthma (.15% reversibility or at least 200 mL), bronchial carcinoma, active pulmonary tuberculosis, known diffuse bronchiectasis, cystic 
fibrosis, or pneumonia (a chest X-ray is not mandatory).
16.   History of chronic colonization of pathogenic organisms resistant to moxifloxacin and/or amoxicillin/clavulanic acid (eg, Pseudomonas aeruginosa, 
meticillin-resistant Staphylococcus aureus).
17. Receiving long-term (.4 consecutive weeks) systemic corticosteroid treatment (.10 mg/day of prednisolone or equivalent).
18. Received short course of systemic corticosteroid treatment within 30 days prior to enrollment.
19. Unable to take oral medication.
20. Life expectancy of less than 6 months.
21. Receiving systemic antibacterial therapy within 30 days prior to study enrollment.
22. Requiring concomitant systemic antibacterial agents.
23. Use of any investigational drug or device within 30 days of screening, or previously enrolled in this study.
24.   Requiring home ventilatory support (patients requiring home/portable oxygen therapy or continuous positive airway pressure for sleep apnea are 
not excluded) and/or those who have a tracheotomy in situ.
25. history of liver function disorders following previous treatment with amoxicillin/clavulanic acid.
26. Receiving disulfiram therapy.
Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus.
Supplementary section 2: Protocol for stratification according to steroid use and geographical region
Steroid use
Prior to randomization, patients are stratified according to steroid usage. Stratum 1 patients were defined as having had coadministration of systemic 
corticosteroids for the current AeCOPD, ie:
 •  were not on long-term low-dose systemic corticosteroid treatment; and
 •  had received treatment with systemic corticosteroids ($50 mg over 10 days) for the current AeCOPD.
Stratum 2 patients were defined as having had no coadministration of systemic corticosteroids for the current AECOPD, ie:
   •  were on long-term low-dose systemic corticosteroid treatment which remained stable or increased minimally during the study treatment 
(cumulative dose ,100 mg over 10 days) for the current AeCOPD; or
 •  had received systemic corticosteroids for the current AeCOPD but at a cumulative dose of ,50 mg over 10 days.
Geographical regions
For the primary analysis, the following geographical regions will be included as separate strata:
 •  Asia Pacific: Australia, China, Hong Kong, Indonesia, Pakistan, the Philippines, Thailand
 •  europe 1: Belgium, germany, Ireland, Latvia, Lithuania, the Netherlands, Switzerland, UK
 •  europe 2 and South Africa: Andorra, Croatia, Czech Republic, greece, Italy, Portugal, South Africa, Spain
 •  Latin America and Canada: Argentina, Mexico, Peru, Brazil, Colombia, Chile, Canada.
The ratio of the sample size of the largest region compared with the smallest region should not be greater than 2:1.
Abbreviation: AeCOPD, acute exacerbations of chronic obstructive pulmonary disease.International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
383
A novel study design in AeCOPD
Supplementary section 3: Clinical and bacteriological response 
categories
Clinical response definitions
•   Clinical improvement: signs and symptoms are improving and 
treatment continues (this category is only available during antibiotic 
therapy).
•   Clinical failure: exacerbation symptoms have not improved or have 
worsened such that additional or alternate systemic antimicrobial and/
or systemic corticosteroid therapy is required.
• Indeterminate: clinical response cannot be determined.
•   Clinical cure: resolution or improvement in the signs and symptoms 
of the exacerbation such that additional or alternate systemic 
antimicrobial and/or systemic corticosteroid therapy is not required.
•   Continued clinical cure: continued absence of acute signs and 
symptoms related to the infection such that additional or alternate 
therapy (systemic antimicrobial and/or systemic corticosteroid) is not 
required.
•   Clinical relapse: reappearance of the signs and symptoms of 
infection such that re-institution of therapy (systemic antimicrobial 
and/or systemic corticosteroid) is required; for the analysis, this will 
be considered clinical failure at the 4 weeks post-therapy and 8 weeks 
post-therapy visits.
Bacteriological response definitions
•   Bacteriological eradication without superinfection or 
reinfection: initial causative pathogen(s) absent, no new pathogen 
isolated after start of study.
•   Presumed eradication: absence of appropriate culture material for 
evaluation because subject has clinically improved on therapy.
• Persistence: initial causative pathogen(s) still present.
•   Presumed persistence: absence of appropriate culture material for 
evaluation, in a subject who has not clinically improved on therapy.
•   Bacteriological eradication with superinfection: initial causative 
pathogen(s) absent, a new pathogen isolated during treatment.
•   Bacteriological eradication with reinfection: initial causative 
pathogen(s) absent, a new pathogen isolated after end of treatment.
•   Eradication with recurrence: original causative organism absent at 
end of therapy, but reappearance of the same organism at or before 8 
weeks post-therapy.
•   Continued eradication: the causative organism(s) is absent at this 
time point.
•   Continued presumed eradication: the absence of appropriate 
culture material for evaluation because the patients have clinically 
improved.
• Indeterminate: bacterial response to the study drug not evaluable.
Supplementary section 4: Subpopulations of interest
• Males, females
• ,65 years of age, and elderly patients ($65 years)
• 2, 3, and $4 previous AeCB episodes in the last 12 months
• Active smokers at study start
• Cardiopulmonary disease (as defined by the MedDRA terms)
• Previous respiratory failure
•   Patients receiving (stratum 1) or not receiving (stratum 2) 
coadministration of systemic steroid administration
•   Patients receiving coadministration of systemic steroid administration, 
irrespective of stratum allocation
•   FeV1 at enrollment according to the following categories: FeV1 ,30% 
of predicted, 30% # FeV1 ,60% of predicted, and FeV1 $60% of 
predicted
•   Previous systemic antimicrobial use in the last 90 days before study 
start (for any reason)
• Patients whose last exacerbation was $63 days before study start
• Patients whose last exacerbation was ,6 months before study start
• Patients with bacteria isolated from sputum at baseline
Abbreviations:  AeCB,  acute  exacerbation  of  chronic  bronchitis;  FeV1,  forced 
expiratory  volume  in  1  second;  MedDRA,  Medical  Dictionary  for  Regulatory 
Activities.